« Return to News | CROs/Service Providers

SynteractHCR launches platform to support trial efficiencies

Friday, June 14, 2013 09:31 AM

San Diego-based SynteractHCR, a full-service CRO, will unveil its Intelligent Clinical Development platform (ICD+) at the upcoming DIA annual meeting in Boston. 

SynteractHCR’s goal is to take time and cost out of the drug development process to deliver successful therapies to patients sooner. ICD+ is the platform by which the company leverages clinical development expertise, appropriate technology and optimized processes, tailored to each client’s needs, to drive solution-oriented efficiencies on a global scale. ICD+ allows sponsors to get to decision points faster, while providing a uniform approach to trials globally to promote consistent standards and high quality.

“As we strive to streamline clinical trials and deliver better therapies in healthcare, we are confident that with ICD+ we offer a great solution to our clients,” says SynteractHCR chief executive Wendel Barr.  

In March 2013, SynteractHCR was formed from the merger of Synteract and Harrison Clinical Research (HCR), and operates from 16 locations worldwide supporting phase I-IV trials.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.